1. No category

Global
Liquid Biopsy
Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016-2026
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
Widespread acceptance of liquid biopsy technique in North America and steady adoption in
developing regions is expected to drive global liquid biopsy market revenues. The global market
is expected to reach US$ 407 Mn in 2016, up from US$ 351 Mn in 2015. North America will
continue to remain the largest market for liquid biopsy, accounting for over 50% share of the
global market.
The minimally-invasive nature and economical affordability of liquid biopsy tests will play a key
role in bolstering demand globally. FDA approvals for non-invasive diagnostic tests for cancers is
expected to have a positive influence on the growth of the market.
Request for sample report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1396
An increasing number of biotechnology and pharmaceutical companies are pushing the demand
for liquid biopsy for anti-cancerous drug development. Moreover, oncologists are more inclined
toward liquid biopsy for cancer detection. Government funding for R&D and clinical trials for
diagnostics, treatment, and prevention are other key factors fuelling adoption of liquid biopsy. In
contrast, higher cost of liquid biopsy compared to conventional diagnostic techniques, and low
awareness regarding liquid biopsy tests can pose challenges to growth.
By bio marker type, circulating tumour cells (CTCs) segment is expected to form the most
attractive market segment, contributing more than 60% of the revenue share to the market. On
the basis of the sample type, the segment for blood sample will reflect the highest growth
potential, with over 93% of the market share by revenues. However, the urine sample segment
is anticipated to witness noticeable growth throughout 2016.
Report
Description
Report Description
By disease indication, lung cancer segment is expected to dominate the market, in terms
of revenues. By end user, cancer institutes are estimated to represent a revenue share of
around 38% -- significantly higher compared to other end-use segments, such as
hospitals, academic institutes, and diagnostic centres.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1396
Some of the key players in the global liquid biopsy market include Genomic Health, Inc.,
Biocept, Qiagen, Inc., Trovagene, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems,
Pathway Genomics Corporation, and Sysmex Corporation. A majority of key companies
are concentrating on mergers, acquisitions, and partnerships; while most of them are
prioritising innovative diagnostics and technological upgrades for better penetration in
developing regional markets.
Long term outlook: The global liquid biopsy market is projected to expand at a CAGR of
21.7% by 2026 end, reaching a value of US$ 2.89 Bn.
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705